Cholesteryl ester transfer protein inhibition and HDL increase: Has the dream ended?

Expert Opinion on Investigational Drugs

Volumn 17, Issue 4, 2008, Pages 445-449

  Athyros, Vasilios G ^a,b   Kakafika, Anna ^a,b   Tziomalos, Konstantinós ^a,b,c   Karagiannis, Asterios ^a,b   Mikhailidis, Dimitri P ^a,c  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b ARISTOTLE UNIVERSITY MEDICAL SCHOOL   (Greece)

^c ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

Author keywords

Anacetrapib; Blood pressure; Cholesteryl ester transfer protein; High density lipoprotein cholesterol

Indexed keywords

2 METHYLPROPANETHIOIC ACID S [2 [1 (2 ETHYLBUTYL)CYCLOHEXYLCARBOXAMIDO]PHENYL] ESTER; ANACETRAPIB; ATORVASTATIN; C REACTIVE PROTEIN; CHOLESTEROL ESTER TRANSFER PROTEIN; CHOLESTEROL ESTER TRANSFER PROTEIN INHIBITOR; HIGH DENSITY LIPOPROTEIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; HYPOCHOLESTEROLEMIC AGENT; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MK 0859; PLACEBO; PRAVASTATIN; TORCETRAPIB; TRIACYLGLYCEROL; UNCLASSIFIED DRUG; ANTILIPEMIC AGENT; CETP PROTEIN, HUMAN; QUINOLINE DERIVATIVE; THIOL DERIVATIVE;

ALDOSTERONE BLOOD LEVEL; ATHEROSCLEROSIS; BICARBONATE BLOOD LEVEL; CARDIOVASCULAR DISEASE; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; DRUG FATALITY; DRUG WITHDRAWAL; DYSLIPIDEMIA; EDITORIAL; FAMILIAL HYPERCHOLESTEROLEMIA; GASTROINTESTINAL SYMPTOM; HUMAN; HYPERLIPIDEMIA; HYPERTRIGLYCERIDEMIA; MONOTHERAPY; POTASSIUM BLOOD LEVEL; RISK FACTOR; RISK REDUCTION; SIDE EFFECT; SODIUM BLOOD LEVEL; SYSTOLIC BLOOD PRESSURE; TREATMENT DURATION; TREATMENT OUTCOME; VASCULAR DISEASE; BLOOD; BLOOD PRESSURE; DRUG ANTAGONISM; DRUG COMBINATION; DRUG DESIGN; DRUG EFFECT; METABOLISM; PATHOPHYSIOLOGY; UPREGULATION;

ANTILIPEMIC AGENTS; BLOOD PRESSURE; CHOLESTEROL ESTER TRANSFER PROTEINS; CHOLESTEROL, HDL; DRUG DESIGN; DRUG THERAPY, COMBINATION; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERLIPIDEMIAS; QUINOLINES; SULFHYDRYL COMPOUNDS; UP-REGULATION;

EID: 42149143445     PISSN: 13543784     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543784.17.4.445     Document Type: Editorial

References (32)

1. Athyros VG, Mikhailidis DP, Kakafika AI, et al. Identifying and attaining LDL-C goals: mission accomplished? Next target: new therapeutic options to raise HDL-C levels. Curr Drug Targets 2007;8:483-8
2. Athyros VG, Papageorgiou AA, Mercouris BR, et al. Treatment with atorvastatin to the National Cholesterol Educational Program goals versus usual care in secondary Coronary Heart Disease prevention. The GREek Atorvastatin and Coronary-heart-disease Evaluation (GREACE) Study. Curr Med Res Opin 2002;18:220-8
3. Athyros V G, Mikhailidis DP, Papageorgiou AA, et al; GREACE Collaborative Group. Effect of atorvastatin on high-density lipoprotein cholesterol and its relationship with coronary events: a subgroup analysis of the GREek Atorvastatin and Coronary heart-disease Evaluation (GREACE) Study. Curr Med Res Opin 2004;20:627-37
4. Barter P, Gotto AM, Larosa JC, et al. HDL cholesterol, very low levels of LDL cholesterol, and cardiovascular events. N Engl J Med 2007;357:1301-10
5. Nicholls SJ, Tuzcu EM, Sipahi I, et al. Statins, high-density lipoprotein cholesterol, and regression of coronary atherosclerosis. J Am Med Assoc 2007;297:499-508
6. Athyros VG, Kakafika A, Karagiannis A, Mikhailidis DP. Statins and regression of coronary atherosclerosis. J Am Med Assoc 2007;297:2197
7. Barter PJ, Brewer HB Jr, Chapman MJ, et al. Cholesteryl ester transfer protein: a novel target for raising HDL and inhibiting atherosclerosis. Arterioscler Thromb Vasc Biol 2003;23:160-7
8. De Grooth GJ, Klerkx AH, Stroes ES, et al. A review of CETP and its relation to atherosclerosis. J Lipid Res 2004;45:1967-74
9. Barter PJ, Caulfield M, Eriksson M; The ILLUMINATE Investigators. Effects of torcetrapib in patients at high risk for coronary events. N Engl J Med 2007;357:2109-22
10. Kastelein JJ, Van Leuven SI, Burgess L; The RADIANCE 1 Investigators. Effect of torcetrapib on carotid atherosclerosis in familial hypercholesterolemia. N Engl J Med 2007;356:1620-30
11. Bots ML, Visseren FL, Evans GW; The RADIANCE 2 Investigators. Torcetrapib and carotid intima-media thickness in mixed dyslipidaemia (RADIANCE 2 study): a randomised, double-blind trial. Lancet 2007;370:153-60
12. Nissen SE, Tardif JC, Nicholls SJ; The ILLUSTRATE Investigators. Effect of torcetrapib on the progression of coronary atherosclerosis. N Engl J Med 2007;356:1304-16
13. Kastelein JJ, Van Leuven SI, Evans GW, et al; The RADIANCE 1 and 2 Study Investigators. Designs of RADIANCE 1 and 2: carotid ultrasound studies comparing the effects of torcetrapib/atorvastatin with atorvastatin alone on atherosclerosis. Curr Med Res Opin 2007;23:885-94
14. Tall AR. CETP inhibitors to increase HDL cholesterol levels. N Engl J Med 2007;356:1364-6
15. Kuivenhoven JA, De Grooth GJ, Kawamura H, et al. Effectiveness of inhibition of cholesteryl ester transfer protein by JTT-705 in combination with pravastatin in type II dyslipidemia. Am J Cardiol 2005;95:1085-8
16. De Grooth GJ, Kuivenhoven JA, Stalenhoef AF, et al. Efficacy and safety of a novel cholesteryl ester transfer protein inhibitor, JTT-705, in humans: a randomized phase II dose-response study. Circulation 2002;105:2159-65
17. Krishna R, Anderson MS, Bergman AJ, et al. Effect of the cholesteryl-ester transfer protein inhibitor, anacetrapib, on lipoproteins in patients with dyslipidaemia and on 24-h ambulatory blood pressure in healthy individuals: two double-blind, randomised placebo-controlled phase I studies. Lancet 2007;370:1907-14
18. Duriez P. CETP inhibition. Lancet 2007;370:1882-3
19. Kee P, Caiazza D, Rye KA, et al. Effect of inhibiting cholesteryl ester transfer protein on the kinetics of high-density lipoprotein cholesteryl ester transport in plasma: in vivo studies in rabbits. Arterioscler Thromb Vasc Biol 2006;26:884-90
20. Brousseau ME, Diffenderfer MR, Millar JS, et al. Effeccs of cholesteryl ester transfer protein inhibition on high-density lipoprotein subspecies, apolipoprotein A-I metabolism, and fecal sterol excretion. Arterioscler Thromb Vasc Biol 2005;25:1057-64
21. Tchoua U, D'Souza W, Mukhamedova N, et al. The effect of cholesteryl ester transport protein overexpression and inhibition on reverse cholesterol transport. Cardiovasc Res. Epub 2008 Jan 16
22. Yvan-Charvet L, Matsuura F, Wang N, et al. Inhibition of cholesteryl ester transfer protein by torcetrapib modestly increases macrophage cholesterol efflux to HDL. Arterioscler Thromb Vasc Biol 2007;27:1132-8
23. Mackness MI, Abbott C, Arrof S, Durrington PN. The role of high density lipoprotein and lipid-soluble antioxidant vitamins in inhibiting low-density lipoprotein oxidation. Biochem J 1993;294:829-34
24. Barter PJ, Rye K-A. High density lipoproteins and coronary heart disease. Atherosclerosis 1996;121:1-12
25. Hirano K, Yamashita S, Nakajima N, et al. Genetic cholesteryl ester transfer protein deficiency is extremely frequent in the Omagari area of Japan. Marked hyperalphalipoproteinemia caused by CETP gene mutation is not associated with longevity. Arterioscler Thromb Vasc Biol 1997;17:1053-9
26. Nagano M, Yamashita S, Hirano K, et al. Molecular mechanisms of cholesteryl ester transfer protein deficiency in Japanese. J Atheroscler Thromb 2004;11:110-21
27. Moriyama Y, Okamura T, Inazu A, et al. A low prevalence of coronary heart disease among subjects with increased high-density lipoprotein cholesterol levels, including those with plasma cholesteryl ester transfer protein deficiency. Prev Med 1998;27:659-267
28. Athyros VG, Kakafika AI, Papageorgiou AA, et al; GREACE Study Collaborative Group. Atorvastatin decreases triacylglycerol-associated risk of vascular events in coronary heart disease patients. Lipids 2007;42:999-1009
29. Sarwar N, Danesh J, Eiriksdottir G, et al. Triglycerides and the risk of coronary heart disease: 10,158 incident cases among 262,525 participants in 29 Western prospective studies. Circulation 2007;115:4510-8
30. Abraham J, Campbell CY, Cheema A, et al. C-reactive protein in cardiovascular risk assessment: a review of the evidence. J Cardiometab Syndr 2007;2:119-23
31. Gazi IF, Tsimihodimos V, Tselepis AD, et al. Clinical importance and therapeutic modulation of small dense low-density lipoprotein particles. Expert Opin Biol Ther 2007;7:53-72
32. Davidson MH, McKenney JM, Shear CL, Revkin JH. Efficacy and safety of torcetrapib, a novel cholesteryl ester transfer protein inhibitor, in individuals with below-average high-density lipoprotein cholesterol levels. J Am Coll Cardiol 2006;48:1774-81